Endo Pharmaceuticals Holdings (ENDP) Reports In-Line Q1 EPS; Reaffirms Outlook

Endo Pharmaceuticals Holdings (NASDAQ: ENDP) reported Q1 EPS of $0.87, in-line with the analyst estimate of $0.87. Revenue for the quarter came in at $691 million versus the consensus estimate of $700.34 million.

Endo Pharmaceuticals Holdings reaffirmed FY2012 guidance.

For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• Laird Superfood, Inc. (LSF) Misses Q2 EPS by 22c ; Offers Guidance
• Bernstein SocGen Group Reiterates Outperform Rating on JD.com, Inc (JD), 'very cheaply valued'